NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results

Second quarter net sales increase 55% and Avenova sales through high-margin pharmacy channel increase 80% over prior year

Affirms 2017 revenue guidance

Conference call begins today at 4:30 p.m. Eastern time

EMERYVILLE, Calif.--()--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and six months ended June 30, 2017 and provides a business update.

“We are affirming revenue guidance for 2017 including our outlook for total sales of $19 million, which represents a 60% increase over 2016.”

“We had record Avenova unit volume through the pharmacy channel during the second quarter, along with an 80% increase in revenue through this channel over the prior year. Our planned shift of sales to the higher-margin pharmacy channel from our legacy in-office direct sales channel continued into the second quarter, and resulted in Avenova sales growth of 48% year-over-year. Importantly, total revenue increased 79% for the first half of 2017 as we continue to be confident in reaching our revenue guidance for the year,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “Our focus on the ophthalmology channel continues to pay off with gross margin on Avenova sales reaching 89%, in line with our expectations for the year. We carefully managed and reduced our cash burn while investing in sales and marketing initiatives to support continued growth, and we continue to believe that our current financial resources will be sufficient to fund operations and our growth strategy throughout 2017.

“As part of our ongoing strategy to make Avenova accessible to an ever-growing number of patients, I am pleased to announce that during the second quarter we teamed up with MedVantx and the world’s largest retailer. Our new partnership provides patients with the option of home delivery of Avenova in all 50 states or pick up at one of thousands of in-store pharmacies across the U.S.

“We expanded our sales organization early this year and we expect our sales to continue to increase as our newer sales representatives gain tenure and become more productive,” he added. “We are affirming revenue guidance for 2017 including our outlook for total sales of $19 million, which represents a 60% increase over 2016.”

Key Second Quarter Metrics

  • Sales of $4.1 million increased 55% year-over-year;
  • Gross margin on Avenova sales reached 89%;
  • Prescription sales into the pharmacy channel were $3.0 million, up 80% year-over-year;
  • New prescribers were nearly 900; and
  • Total number of medical professionals who have prescribed Avenova exceeded 10,600, up 21% year-over-year and up 9% from the first quarter of 2017.

Second Quarter 2017 Financial Results

Net sales for the second quarter of 2017 increased 55% to $4.1 million from $2.7 million for the second quarter of 2016. Total gross profit margin improved to 83% for the second quarter of 2017 from 82% for the second quarter of 2016. The gross profit margin on Avenova sales for the second quarter of 2017 improved to 89% from 85% for the prior-year period.

Operating loss for the second quarter of 2017 improved 22% to $1.8 million from $2.2 million for the second quarter of 2016. Sales and marketing expenses for the second quarter of 2017 were $3.4 million compared with $2.9 million for the prior-year period, with the increase primarily due to an increase in the number of sales representatives and increased sampling and marketing programs. G&A expenses for the second quarter of 2017 were $1.7 million compared with $1.3 million for the prior-year period, with the increase primarily resulting from higher stock-based compensation expense and increased expenses to support the employee salesforce, partially offset by lower lease expenses. R&D expenses declined to $70,000 for the second quarter of 2017 from $0.3 million for the second quarter of 2016, primarily due to the Company’s focus on Avenova commercialization.

Non-cash gain on the change of fair value of warrant liability for the second quarter of 2017 was $15,000 compared with a non-cash loss of $424,000 for the second quarter of 2016.

The net loss for the second quarter of 2017 was $1.7 million, or $0.11 per share on a basic basis, compared with a net loss for the second quarter of 2016 of $2.7 million, or $0.36 per share on a basic basis.

Six-Month 2017 Financial Results

Net sales for the six months ended June 30, 2017 were $7.8 million, up 79% from $4.4 million for the six months ended June 30, 2016. Total gross profit margin was 84% for the first half of 2017, compared with 75% for the first half of 2016. Gross profit margin on Avenova sales was 89% the first half of 2017, compared with 82% for the first half of 2016.

Operating loss for the first six months of 2017 was $5.5 million, a 20% improvement from $6.9 million for the comparable period in 2016. Sales and marketing expenses for the six months ended June 30, 2017 increased 19% to $7.1 million and G&A expenses increased 62% to $4.8 million, both compared with the six months ended June 30, 2016. R&D expenses for the first six months of 2017 decreased 89% to $0.1 million compared with the first six months of 2016.

Non-cash loss on the change of fair value of warrant liability for the first six months of 2017 was $220,000 compared with a non-cash loss of $809,000 for the first six months of 2016.

The net loss for the six months ended June 30, 2017 was $5.7 million, or $0.38 per share on a basic basis, compared with a net loss for the six months ended June 30, 2016 of $7.8 million, or $1.35 per share on a basic basis.

NovaBay reported cash and cash equivalents of $5.7 million as of June 30, 2017, compared with $9.5 million as of December 31, 2016.

The Company used $1.6 million in cash to fund operations during the second quarter of 2017, a significant improvement from $2.7 million used during the second quarter of 2016. The decrease in cash usage was primarily due to higher sales of Avenova.

2017 Financial Outlook

NovaBay is affirming total sales and gross profit margin guidance for 2017. The Company’s expectations are as follows:

  • Total sales of $19 million, up 60% over 2016; and
  • Gross profit margin on Avenova sales in the high 80 percentiles.

Conference Call

NovaBay management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 800-608-8202 from within the U.S. or 702-495-1913 from outside the U.S., with the conference identification number 56306358.

A live webcast of the call will be available at http://novabay.com/investors/events and will be archived for 90 days.

A replay of the call will be available beginning two hours after call completion through 11:59 p.m. Eastern time September 9, 2017 by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 56306358.

About Avenova®

Avenova is NovaBay Pharmaceuticals’ main commercial focus. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Forward-Looking Statements

This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our expected annual revenue, expected operating losses, gross margin, the future sales of our products, what we believe to be sufficient future financial resources, and generally the Company’s expected future financial results. Forward-looking statements can be identified with words like (and variations of): “believe,” and “expect.” These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company’s intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Contacts
For NovaBay Avenova purchasing information, please contact:
800-890-0329
www.Avenova.com

 
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands)
 
  June 30,   December 31,
2017 2016
ASSETS
Current assets:
Cash and cash equivalents $ 5,722 $ 9,512
Accounts receivable, net of allowance for doubtful accounts ($48 and $10 at June 30, 2017 and December 31, 2016, respectively) 3,601 2,120
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimate net realizable value adjustments of $149 and $196 at June 30, 2017 and December 31, 2016, respectively) 672 873
Prepaid expenses and other current assets   972     1,966  
Total current assets 10,967 14,471
Property and equipment, net 462 371
Other assets   641     539  
TOTAL ASSETS $ 12,070   $ 15,381  
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities:
Current liabilities:
Accounts payable $ 908 $ 455
Accrued liabilities 1,655 2,007
Deferred revenue   2,172     1,861  
Total current liabilities 4,735 4,323
Deferred revenues - non-current 1,997 1,986
Deferred rent 300 327
Warrant liability 1,608 1,446
Other liabilities   221     198  
Total liabilities   8,861     8,280  
 
Stockholders' equity :
Preferred stock: 5,000 shares authorized; none outstanding at June 30, 2017 and December 31, 2016

Common stock, $0.01 par value; 240,000, shares authorized 15,309 and 15,269 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively

153 153
Additional paid-in capital 112,477 110,619
Accumulated deficit   (109,421 )   (103,671 )
Total stockholders' equity   3,209     7,101  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 12,070   $ 15,381  
 
 
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except per share data)
 
    Three Months Ended       Six Months Ended
June 30, June 30,
2017     2016 2017     2016
Sales:        
Product revenue, net $ 4,094 $ 2,654 $ 7,788 $ 4,309
Other revenue,net   28     9     35     73  
Total sales, net 4,122 2,663 7,823 4,382
 
Product cost of goods sold   698     479     1,286     1,090  
Gross profit   3,424     2,184     6,537     3,292  
 
Research and development 70 278 132 1,211
Sales and marketing 3,376 2,853 7,116 5,997
General and administrative   1,735     1,293     4,823     2,975  
Total operating expenses   5,181     4,424     12,071     10,183  
Operating Loss (1,757 ) (2,240 ) (5,534 ) (6,891 )
 
Non-cash gain (loss) on changes in fair value of warrant liability 15 (424 ) (220 ) (809 )
Other income (expense), net   4     (24 )   6     (65 )
 
Loss before provision for income taxes (1,738 ) (2,688 ) (5,748 ) (7,765 )
Provision for income tax   -     (2 )   (1 )   (2 )
Net loss and comprehensive loss

$

(1,738

)

$ (2,690 ) $ (5,749 ) $ (7,767 )
 
Net loss per share attributable to common stockholders (basic and diluted) $ (0.11 ) $ (0.36 ) $ (0.38 ) $ (1.35 )
 
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock 15,308 7,407 15,296 5,746
 

Contacts

NovaBay Contact
Jack McGovern
Chief Financial Officer
510-899-8800
Jmcgovern@novabay.com
or
Investor Contact
LHA Investor Relations
Jody Cain
310-691-7100
Jcain@lhai.com

Recent Stories

RSS feed for NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc.